JPRN-UMIN000004096已完成未知
A study to evaluate efficacy and safety of docetaxel combined with dexamethasone in patients with hormone refractory prostate cancer; JMTO PCa10-01 - A study of docetaxel and dexamethason for hormone refractory prostate cancer; JMTO PCa10-01
The Japan-Multinational Trial Organization0 个研究点目标入组 75 人开始时间: 2010年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1. No prior cyto-toxic chemotherapy and/or molecular targeting therapy, including mono-therapy of estramustine. 2. Infection. 3. Fever with suspicion of infectious disease. 4. Interstitial pneumonitis and pulmonary fibrosis.
研究者
相似试验
已完成
不适用
A phase I and randomised phase II study of docetaxel and RAD001 (Everolimus) in advanced / recurrent or metastatic squamous cell carcinoma of the head and neckAdvanced / recurrent or metastsatic squamous cell carcinoma of the head and neck.squamous cell carcinoma of the head and neckCancerISRCTN73814534niversity College London (UCL) (UK)120
进行中（未招募）
不适用
A phase II study of the safety and efficacy of doxycycline administered cyclically in patients suffering from Transthyretin Amiloidosis ATTR - NDTransthyretin amyloidosis ATTRMedDRA version: 6.1Level: HLGTClassification code 10034606EUCTR2006-000012-24-ITOSPEDALE POLICLINICO S. MATTEO10
进行中（未招募）
1 期
A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma - Docetaxel +/- AZD6244 in MelanomaAdvanced metastatic melanomaEUCTR2009-018153-23-GBniversity of Oxford80
进行中（未招募）
不适用
A study of DoTiNurad aiming to treat hyperuricemia with CKDPatients with hyperuricemia whose renal function is in the GFR range of G1 to G4JPRN-jRCTs061210079Wada Jun100
进行中（未招募）
1 期
Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer. - MADONNAmetastatic HER2-negative breast cancerEUCTR2008-001090-15-DEniversitätsklinikum Heidelberg288